These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33916702)

  • 1. Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus.
    García-Crespo C; Gallego I; Soria ME; de Ávila AI; Martínez-González B; Vázquez-Sirvent L; Lobo-Vega R; Moreno E; Gómez J; Briones C; Gregori J; Quer J; Domingo E; Perales C
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33916702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Two-Level, Intramutant Spectrum Haplotype Profile of Hepatitis C Virus Revealed by Self-Organized Maps.
    Delgado S; Perales C; García-Crespo C; Soria ME; Gallego I; de Ávila AI; Martínez-González B; Vázquez-Sirvent L; López-Galíndez C; Morán F; Domingo E
    Microbiol Spectr; 2021 Dec; 9(3):e0145921. PubMed ID: 34756074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
    Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
    Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.
    Contreras AM; Hiasa Y; He W; Terella A; Schmidt EV; Chung RT
    J Virol; 2002 Sep; 76(17):8505-17. PubMed ID: 12163570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity.
    Brochot E; Duverlie G; Castelain S; Morel V; Wychowski C; Dubuisson J; François C
    Antivir Ther; 2007; 12(5):805-13. PubMed ID: 17713164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.
    Galli A; Mens H; Gottwein JM; Gerstoft J; Bukh J
    Sci Rep; 2018 Mar; 8(1):4619. PubMed ID: 29545599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino Acid Mutations in the NS4A Region of Hepatitis C Virus Contribute to Viral Replication and Infectious Virus Production.
    Murayama A; Sugiyama N; Suzuki R; Moriyama M; Nakamura N; Mochizuki H; Wakita T; Kato T
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad and Dynamic Diversification of Infectious Hepatitis C Virus in a Cell Culture Environment.
    Gallego I; Soria ME; García-Crespo C; Chen Q; Martínez-Barragán P; Khalfaoui S; Martínez-González B; Sanchez-Martin I; Palacios-Blanco I; de Ávila AI; García-Cehic D; Esteban JI; Gómez J; Briones C; Gregori J; Quer J; Perales C; Domingo E
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.
    Hofmann WP; Polta A; Herrmann E; Mihm U; Kronenberger B; Sonntag T; Lohmann V; Schönberger B; Zeuzem S; Sarrazin C
    Gastroenterology; 2007 Mar; 132(3):921-30. PubMed ID: 17383421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent.
    Mejer N; Galli A; Ramirez S; Fahnøe U; Benfield T; Bukh J
    Virology; 2020 Jan; 540():132-140. PubMed ID: 31778898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
    J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
    Mejer N; Fahnøe U; Galli A; Ramirez S; Weiland O; Benfield T; Bukh J
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
    Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
    MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
    Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
    J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
    Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
    J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
    Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
    Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.